Literature DB >> 33199193

Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy.

Yong Liu1, Patrick L Leslie2, Yanping Zhang3.   

Abstract

The tumor-suppressor protein p53 is mutated in approximately half of all cancers, whereas the p53 signaling network is perturbed in almost all cancers. In response to different stress stimuli, p53 selectively activates genes to elicit a cell survival or cell death response. How p53 makes the decision between life and death remains a fascinating question and an exciting field of research. Understanding how this decision is made has major implications for improving cancer treatments, particularly in recently evolved immune checkpoint inhibition therapy. We highlight progress and challenges in understanding the mechanisms governing the p53 life and death decision-making process, and discuss how this decision is relevant to immune system regulation. Finally, we discuss how knowledge of the p53 pro-survival and pro-death decision node can be applied to optimize immune checkpoint inhibitor therapy for cancer treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer; cancer immunotherapy; cancer therapeutics; cell death; cell survival; p53

Mesh:

Substances:

Year:  2020        PMID: 33199193      PMCID: PMC7889652          DOI: 10.1016/j.trecan.2020.10.005

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  97 in total

1.  p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Authors:  Liz J Valente; Daniel H D Gray; Ewa M Michalak; Josefina Pinon-Hofbauer; Alex Egle; Clare L Scott; Ana Janic; Andreas Strasser
Journal:  Cell Rep       Date:  2013-05-09       Impact factor: 9.423

2.  Kinetics of p53 binding to promoter sites in vivo.

Authors:  S T Szak; D Mays; J A Pietenpol
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

3.  Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.

Authors:  Gang Guo; Miao Yu; Wei Xiao; Esteban Celis; Yan Cui
Journal:  Cancer Res       Date:  2017-03-09       Impact factor: 12.701

4.  Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.

Authors:  Sonja Textor; Nathalie Fiegler; Annette Arnold; Angel Porgador; Thomas G Hofmann; Adelheid Cerwenka
Journal:  Cancer Res       Date:  2011-07-15       Impact factor: 12.701

Review 5.  p53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Authors:  Flore Kruiswijk; Christiaan F Labuschagne; Karen H Vousden
Journal:  Nat Rev Mol Cell Biol       Date:  2015-07       Impact factor: 94.444

6.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors:  Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

7.  The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.

Authors:  Maria Shatz; Daniel Menendez; Michael A Resnick
Journal:  Cancer Res       Date:  2012-06-06       Impact factor: 12.701

8.  p53 Pulses Diversify Target Gene Expression Dynamics in an mRNA Half-Life-Dependent Manner and Delineate Co-regulated Target Gene Subnetworks.

Authors:  Joshua R Porter; Brian E Fisher; Eric Batchelor
Journal:  Cell Syst       Date:  2016-04-07       Impact factor: 10.304

9.  Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate.

Authors:  Chad D Knights; Jason Catania; Simone Di Giovanni; Selen Muratoglu; Ricardo Perez; Amber Swartzbeck; Andrew A Quong; Xiaojing Zhang; Terry Beerman; Richard G Pestell; Maria Laura Avantaggiati
Journal:  J Cell Biol       Date:  2006-05-22       Impact factor: 10.539

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more
  6 in total

Review 1.  The Roles of microRNAs in Cancer Multidrug Resistance.

Authors:  Lucia Pavlíková; Mário Šereš; Albert Breier; Zdena Sulová
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

2.  Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors.

Authors:  Yafeng Wang; Guiquan Zhang; Qingzhou Meng; Shisheng Huang; Panpan Guo; Qibin Leng; Lingyun Sun; Geng Liu; Xingxu Huang; Jianghuai Liu
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

Review 3.  Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction.

Authors:  Jinhui Guo; Jie Zhao; Litao Sun; Chen Yang
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

4.  ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma.

Authors:  Yu Zhang; Shujie Pang; Bo Sun; Minbo Zhang; Xiaoxiao Jiao; Linying Lai; Yiting Qian; Ning Yang; Wenzhuo Yang
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

5.  HPV16 E6-Activated OCT4 Promotes Cervical Cancer Progression by Suppressing p53 Expression via Co-Repressor NCOR1.

Authors:  Shujuan Shu; Zhi Li; Liu Liu; Xia Ying; Yina Zhang; Ting Wang; Xiaoye Zhou; Peiyue Jiang; Weiguo Lv
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

6.  NUAK2 and RCan2 participate in the p53 mutant pro-tumorigenic network.

Authors:  Eleonora Mammarella; Carlotta Zampieri; Emanuele Panatta; Gerry Melino; Ivano Amelio
Journal:  Biol Direct       Date:  2021-08-04       Impact factor: 4.540

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.